R
Robert Goldman
Researcher at Sunovion
Publications - 117
Citations - 7573
Robert Goldman is an academic researcher from Sunovion. The author has contributed to research in topics: Lurasidone & Schizophrenia. The author has an hindex of 35, co-authored 110 publications receiving 7064 citations. Previous affiliations of Robert Goldman include Wayne State University & Albert Einstein College of Medicine.
Papers
More filters
Journal ArticleDOI
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
Delbert Robinson,Margaret G. Woerner,Jose Alvir,Robert M. Bilder,Robert Goldman,Stephen Geisler,A. Koreen,Brian B. Sheitman,Miranda Chakos,David Mayerhoff,Jeffrey A. Lieberman +10 more
TL;DR: There is a high rate of relapse within 5 years of recovery from a first episode of schizophrenia and schizoaffective disorder, and this risk is diminished by maintenance antipsychotic drug treatment.
Journal ArticleDOI
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.
Robert M. Bilder,Robert Goldman,Delbert Robinson,G. Reiter,Lisa Bell,John A. Bates,Elizabeth Pappadopulos,Deborah F. Willson,Jose Maria J. Alvir,Margaret G. Woerner,Stephen Geisler,John M. Kane,Jeffrey A. Lieberman +12 more
TL;DR: A large generalized deficit and more subtle differential deficits were observed even in patients with less severe generalized deficit, but the pattern was unlike the amnestic syndrome and probably reflects different mechanisms.
Journal ArticleDOI
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Robert M. Bilder,Robert Goldman,Jan Volavka,Pál Czobor,Matthew J. Hoptman,Brian Sheitman,Jean Pierre Lindenmayer,Leslie Citrome,Joseph P. McEvoy,Michal Kunz,Miranda Chakos,Thomas B. Cooper,Terri L. Horowitz,Jeffrey A. Lieberman +13 more
TL;DR: Patients with a history of suboptimal response to conventional treatments may show cognitive benefits from newer antipsychotic drugs, and there may be differences between atypical antipsychotics drugs in their patterns of cognitive effects.
Journal ArticleDOI
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Delbert Robinson,Margaret G. Woerner,Jose Alvir,Stephen Geisler,A. Koreen,Brian Sheitman,Miranda Chakos,David Mayerhoff,Robert M. Bilder,Robert Goldman,Jeffrey A. Lieberman +10 more
TL;DR: Patients with first-episode schizophrenia and schizoaffective disorder have high rates of response to antipsychotic treatment; there are specific clinical and pathobiologic predictors of response.
Journal ArticleDOI
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Terry E. Goldberg,Robert Goldman,Katherine E. Burdick,Anil K. Malhotra,Todd Lencz,Raman C. Patel,Woerner M,Nina R. Schooler,John M. Kane,Delbert G. Robinson +9 more
TL;DR: The cognitive improvements observed in the trial were consistent in magnitude with practice effects observed in healthy controls, suggesting that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (ie, exposure, familiarity, and/or procedural learning).